ANNX
NASDAQ · Biotechnology
Annexon Inc
$5.11
-0.38 (-6.92%)
Financial Highlights (FY 2025)
Revenue
226.99M
Net Income
-28,556,645
Gross Margin
35.4%
Profit Margin
-12.6%
Rev Growth
+7.5%
D/E Ratio
0.32
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 35.4% | 35.4% | 35.4% |
| Operating Margin | -10.8% | -9.3% | -9.5% |
| Profit Margin | -12.6% | -10.3% | -12.1% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 226.99M | 205.43M | 221.74M |
| Gross Profit | 80.31M | 72.68M | 78.45M |
| Operating Income | -24,488,878 | -19,122,081 | -21,127,158 |
| Net Income | -28,556,645 | -21,219,491 | -26,718,856 |
| Gross Margin | 35.4% | 35.4% | 35.4% |
| Operating Margin | -10.8% | -9.3% | -9.5% |
| Profit Margin | -12.6% | -10.3% | -12.1% |
| Rev Growth | +7.5% | +20.0% | +0.3% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 215.50M | 242.07M | 240.37M |
| Total Equity | 664.85M | 638.26M | 631.14M |
| D/E Ratio | 0.32 | 0.38 | 0.38 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -33,644,452 | -28,464,345 | -32,841,743 |
| Free Cash Flow | -13,512,889 | -15,079,405 | -14,899,369 |